We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, and Mec-3 domain only 4 (LMO4) in pretreatment tumor samples from 91 erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations in whom breast cancer gene 1 (BRCA1) expression and the concomitant presence of the EGFR T790M mutation had previously been assessed.
In conclusion, reducing the expression of ISL1 suppresses proliferation, migration, invasion, and angiogenesis in breast cancer, suggesting that ISL1 might serve as a novel molecular therapy target in breast cancer.